Novo, SK Group and Amgen have participated in a series C round for the precision therapy developer that has increased its total funding to at least $150m.
Pharmaceutical firm Novo Holdings has led a $125m series C round for Singapore-based precision therapy developer Hummingbird Bioscience that featured pharmaceutical firm Amgen and diversified conglomerate SK Group.
The round also included EDBI, Frazier Healthcare Partners, Octagon Capital, Droia Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge and Altrium Capital Management.
Heritas Capital Management and Mirae Asset Venture Investments, a subsidiary of investment management firm Mirae Asset Global Investments, filled out the round, in which Amgen…
